Horizon Pharma plc

BIO CEO & Investor Conference

February 8, 2016

HORIZON PHARMA

Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, statements related to Horizon Pharma's strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, expected impact, timing and potential benefits from recent and future transactions, expectations regarding development programs and clinical plans, timing of regulatory events and other statements that are not historical facts. These forward-looking statements are based on Horizon Pharma's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Horizon Pharma's ability to complete any future acquisitions on anticipated terms; risks associated with business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of any acquisition will not be realized; risks related to future opportunities and plans for Horizon Pharma, including, without limitation, uncertainty of the expected financial performance and results of Horizon Pharma following completion of any acquisition; disruption from any future acquisition, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; and the possibility that if the combined company does not achieve the perceived benefits of any future acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Horizon Pharma's shares could decline, as well as other risks related to Horizon Pharma's business, including the ability to grow sales and revenues from existing medicines and its ability to increase sales of its existing medicines; Horizon Pharma's ability to successfully execute its commercial and acquisition strategies and achieve projected financial results for 2015, 2016 and other long-term financial metrics; the fact that past financial or operating results are not a guarantee of future results; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including potential changes in healthcare laws and regulations; the availability of coverage and adequate reimbursement and pricing from government and third-party payers and risks relating to the success of Horizon's patient support program; risks associated with clinical development and regulatory approvals, including potential delays in initiating and completing studies and filing for and obtaining regulatory approvals, whether data from clinical studies will support regulatory approval, and whether clinical results will be consistent with data from animal models; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon Pharma's filings and reports with the SEC, including in the Annual Report on Form 10-K for the year ended December 31, 2014, and subsequent quarterly reports on Form 10-Q. Horizon Pharma undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, except as required by applicable law or regulation.

Note Regarding Use of Non-GAAP Financial Measures

Horizon Pharma provides certain financial measures such as EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA, that include adjustments to GAAP figures. These adjustments to GAAP exclude the bargain purchase gain related to the acquisition of Vidara, acquisition transaction related expenses, loss on induced debt conversion, loss on debt extinguishment, secondary offering expenses, as well as non-cash items such as stock compensation, depreciation and amortization, accretion, non-cash interest expense and other non-cash adjustments such as the increase or decrease in the fair value of the embedded derivative associated with the Company's prior convertible senior notes. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred.

Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company's operational results, trends and expectations. In addition, these non-GAAP financial measures are among the indicators Horizon's management uses for planning and forecasting purposes and measuring the Company's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. The Company has not provided a reconciliation of full year 2015 or 2016 adjusted EBITDA outlook to a net income (loss) outlook because certain items that are a component of net income (loss) but not part of adjusted EBITDA, such as the gain (loss) on derivative revaluation associated with the convertible senior notes, stock compensation, acquisition related expenses and certain purchase accounting items such as intangibles and step-up inventory, cannot be reasonably projected, either due to the significant impact of changes in Horizon's stock price on derivative revaluation and stock compensation, or the variability associated with acquisition related expenses and purchase accounting items due to timing and other factors.

Horizon Pharma: When Patients Benefit, Everyone Benefits

Patients, Providers, Our Company, Our Shareholders & Healthcare System

- **Helping people live better lives by building a biopharmaceutical company of tomorrow.**
- **Putting patients first by redefining how they access their medicines.**
- **Investing in differentiated medicines that address the challenges faced by patients living with rare diseases.**
- **Fast-growing, profitable company driven by a highly successful commercial model diversified across three business units.**
- **Strong cash flows enabling a disciplined and proven business development strategy.**

LAILA – Age 10 – California RAVICTI Patient; suffers from a Urea Cycle Disorder (UCD)

Redefining the Biopharma Business Model

Built Commercial Critical Mass First; Expanding with Rare Disease Focus

Orphan

- ACTIMMUNE® (Interferon gamma-1b)
- BUPHENYL® (sodium phenylbutyrate)
- RAVICTI® (glycerol phenylbutyrate) Oral Liquid

Rheumatology

- RAYOS® (1) (Prednisone) Delayed-release Tablets
- PENNSAID® (2) (diclofenac sodium topical solution) 2% w/w
- Krystexxa® (pegloticase) Injection, 8mg/mL, for Intravenous Infusion

Primary Care

- DUEXIS® (ibuprofen and famotidine) Tablets 800 mg/26.6 mg
- VIMOVO® (naproxen/esomeprazole magnesium) 375/20 -500/20 mg delayed-release tablets
- PENNSAID® (2) (diclofenac sodium topical solution) 2% w/w
- MIGERGOT® (ergotamine tartrate & caffeine suppositories)

Nine Medicines Across Three Business Units

Four of Nine Medicines are for Rare Diseases

(1) RAYOS is known as LODOTRA outside the United States.
(2) PENNSAID 2% sold by both the Primary Care and Rheumatology sales forces.

= orphan medicine

HORIZON PHARMA

2015 Was a Record Breaking Year for Horizon Pharma

Exceptional Financial Results; Achieved Clinical and M&A Milestones

Guidance of $750 to $760mm in 2015 net sales (1)

- *More than DOUBLE 2014 net sales*

Guidance of $350 to $360mm in 2015 adjusted EBITDA (1)

- *More than TRIPLE 2014 adjusted EBITDA*

Initiated ACTIMMUNE Phase 3 trial in Friedreich's ataxia (FA) and Phase 1 trial in cancer

- *Expect FA data December 2016*
- *$500mm to $1bn peak net sales opportunity*

Received European regulatory approval for RAVICTI

- *Expect commercial launch in 2017*

Acquired Hyperion (RAVICTI/BUPHENYL) and Announced Crealta (KRYSTEXXA) acquisition

- *Hyperion expected to generate $100mm in 2016 adjusted EBITDA; Crealta expected to add $45 to $50mm in adjusted EBITDA in 1st year*

(1) Represents financial guidance issued on Nov. 6, 2015. By this presentation Horizon is not updating or confirming the prior guidance.

Focused Development Pipeline

ACTIMMUNE FA and RAVICTI (two months - two years) Key Financial Upside

ACTIMMUNE® (Interferon gamma-1b)

- Friedreich's ataxia (FA)
- Autosomal Dominant Osteopetrosis
- Combo cancer therapy w/OPDIVO®(1)
- Next-generation formulation

RAVICTI® (glycerol phenylbutyrate) Oral Liquid

- Urea Cycle Disorders
  - Two months to two years of age
  - Birth to 2 months of age

RAYOS® (Prednisone) Delayed-release Tablets

- PMR (Dose-sparing)
- Lupus (Address fatigue)

Krystexxa® (pegloticase) Injection, 8mg/mL, for Intravenous Infusion

- Immunogenicity



(1) Registered trademark of Bristol-Myers Squibb

HORIZON PHARMA

Strong Footprint in Rare Diseases

ACTIMMUNE in FA Offers Transformational Upside ($500mm – $1bn annually)

Valuable, Growing Medicines in Current Indications

- **$265mm annual net sales run rate**
- **Current indications with peak annual U.S. net sales opportunity of ~$500mm[(1)] in 2020**
- **Attractive contribution margins**
- **Long-life assets**
- **Expansion opportunities Ex-U.S.**

Significant Potential Upside with Additional Indications

- **FA Phase 3 trial underway[(2)] with late 2016 read-out**
- **Combination therapy with OPDIVO® in cancer[(3)]**
- **Annual U.S. net sales opportunity of ~$800mm - $1.5Bbn[(1)] in 2020**

(1) Horizon estimate.
(2) Use of ACTIMMUNE in FA is investigational only, and safety and efficacy has not been established for use in FA. For further information see www.ACTIMMUNE.com.
(3) Use of ACTIMMUNE with OPDIVO® is investigational only, and safety and efficacy has not been established for use with any PD-1 and PD-L1 inhibitor. For further information see www.ACTIMMUNE.com. Registered trademark of Bristol-Myers Squibb.

ACTIMMUNE in Friedreich's Ataxia

~$500mm – $1bn[1] U.S. Annual Net Sales Opportunity

Friedreich's Ataxia

- 85% of diagnosed patients exhibit symptoms before the age of 12
- Life-shortening
  - Life span is 30 to 40 years of age
- No FDA approved treatment
- Current approach
  - Monitor symptoms
  - Most patients take vitamins and antioxidants

Prevalence/Commercial Opportunity

- Prevalence
  - ~3,700 U.S.
- Patients in Friedreich's Ataxia Research Alliance (FARA) patient registry
  - 2,400 globally
  - ~1,500 U.S. patients and growing

Note: Use of ACTIMMUNE in FA is investigational only, and safety and efficacy has not been established for use in FA. For further information, see www.ACTIMMUNE.com.
(1) Horizon estimate.

ACTIMMUNE Phase 3 Trial in FA

Enrollment Greater Than 50% at Year-End 2015

Patient Enrollment Currently >50%

- More than 50 percent enrolled to-date
- Target date for full enrollment of 90 patients is mid-year 2016
- Identifying and enrolling patients via FARA patient registry

Potential Clinical and Regulatory Milestones

- Data available December 2016
- sBLA submission in Q1 2017
- Potential FDA approval in Q3 2017 (Fast Track Designation)

Note: Use of ACTIMMUNE in FA is investigational only, and safety and efficacy has not been established for use in FA. For further information see www.ACTIMMUNE.com.

ACTIMMUNE with PD-1/PD-L1 Inhibitors

~$300mm – $500mm[1] U.S. Annual Net Sales Opportunity

Phase 1 Dosing Trial Initiated December 2015

- **In collaboration with Fox Chase Cancer Center**
- **ACTIMMUNE in combination with OPDIVO® in advanced solid tumors (kidney and bladder cancers)**

Significant investments in PD-1/PD-L1 checkpoint inhibitors

- **Two currently approved medicines**
  - **KEYTRUDA® (pembrolizumab) – Merck[2]**
  - **OPDIVO® (nivolumab) – BMS[3]**

Analysts project PD-1/PD-L1 checkpoint inhibitors market >$30B

Note: Use of ACTIMMUNE with PD-1 and PD-L1 inhibitors is investigational only, and safety and efficacy has not been established for use with any PD-1 and PD-L1 inhibitor. For further information see www.ACTIMMUNE.com.

(1) Horizon estimate in kidney and bladder cancers.
(2) Registered trademark of Merck.
(3) Registered trademark of Bristol-Myers Squibb.

RAVICTI U.S. Label Expansion

Q2 2016 Submission of sNDA for Two Months to Two Years of Age

Birth to Two Years of Age

- **Design:** **Open label design to assess the safety, efficacy and PK of RAVICTI in pediatric patients under two years of age**
- **Subjects:** **UCD patients up to two years of age**
- **Sites:** **U.S. sites**
- **Target dates:**

  Two months – two years

  – **sNDA submission:** **Q2 2016**

  Birth – two months

  – **sNDA submission:** **Q1 2018**

Primary Care/Rheumatology Commercial Model

Patient Focused with Continued Best-in-Class Execution

Primary Care Brands

DUEXIS®
(ibuprofen and famotidine) Tablets
800 mg/26.6 mg

VIMOVO®
(naproxen/esomeprazole magnesium)
375/20-500/20 mg delayed-release tablets

PENNSAID®
(diclofenac sodium topical solution) 2% w/w

MIGERGOT®
(ergotamine tartrate & caffeine suppositories)

Rheumatology Brands

RAYOS®
(Prednisone) Delayed-release Tablets

Krystexxa®
(pegloticase) Injection, 8mg/mL, for Intravenous Infusion

PENNSAID®
(diclofenac sodium topical solution) 2% w/w

HORIZON PHARMA

VIMOVO and DUEXIS

Innovative Medicines Addressing Unmet Medical Need in Clinical Practice

Non-Compliance and Associated Morbidity and Mortality PROVEN

>25 Years since NSAID+GI Protection Availability

NSAID-Induced GI Toxicity

- GI intolerance incidence: up to 50%[1]
- Endoscopic ulcers incidence: 15-46%[2]
- Leads to 107K hospitalizations and 16.5K deaths per year[3]

PROVEN Poor Physician and Patient Compliance

- 76% of MDs do not prescribe concomitant GI therapy[4]
- 61% of patients non-compliant by the 3rd prescription[5]

Data PROVES GI Protective Agents NOT Utilized in Clinical Practice

***DUEXIS & VIMOVO** are **novel, proprietary formulations** of two of the most prescribed NSAIDs combined with a GI protectant in a single pill*

(1) Singh and Rosen Ramey. J Rheumatol. 1998;51(suppl):8–16.
(2) Geis et al. J Rheumatol. 1996;18:11–14.
(3) M.Wolfe, et.al.; Gastrointestinal Toxicity of Nonsteroidal Anti-inflammatory Drugs; NEJM; vol. 340; no. 24; June 1999.
(4) BMC Musculoskeletal Disorders 2006, 7:79.
(5) Sturkenboom, et.al.; Aliment Pharmacol Ther 2003; 18:1137-1147.

HORIZON PHARMA

Horizon Pharma is Committed to Ensuring Patient Access to the Medicines their Physicians Prescribe

Patients Receive Horizon's Clinically Differentiated Medicines with Minimal Out-of-Pocket Costs

HORIZON CARES
IMPROVING ACCESS. SUPPORTING CARE.™

Primary Care & Rheumatology(1)	Co-pay Assistance	Affordable Patient Co-pay for Rejected Rx's
Orphan	Reimbursement Support; Clinical Nurse Program	Patient Assistance; Co-pay Assistance

(1) Available to commercial patients only.

Exceptional TRx Growth Across All Medicines

Primary Care Estimated Year Over Year TRx Growth of Over 90%(1)

Continued Strong Execution and Growth of All Medicines

Quarterly Growth (Y/Y)

	Q4 2015 Estimated(1)	Q4 2014 Actual	% Growth
DUEXIS	147,822	76,222	94%
VIMOVO	104,716	82,937	26%
PENNSAID 2%	111,381	16,505	575%
Primary Care Total	363,919	175,664	107%
RAYOS	10,917	4,383	149%

Annual Growth (Y/Y)

	FY 2015 Estimated1	FY 2014 Actual	% Growth
DUEXIS	500,492	262,758	90%
VIMOVO	384,928	310,183	24%
PENNSAID 2%	320,175	58,182	450%
Primary Care Total	1,205,595	631,123	91%
RAYOS	33,376	14,492	130%

Two-Year Growth Rate (2015 vs 2013) for All Medicines is 184%(1)

(1) IMS NPA data, which is estimated based on actual 2015 Monthly data through November and Weekly IMS NPA data for December 2015.

Horizon Pharma Growth Driven by Rapid Volume Growth[(1)]

Volume +189% vs. Price +16%

Seven-Quarter Prescription Growth of 189% Since Q1 2014

Average net realized price increased 9% annualized, 16% cumulatively since Q1 2014

Quarterly Average Net Realized Price (ANRP) and Prescription Volumes 1/1/14 to 9/30/15



(1) DUEXIS, VIMOVO, PENNSAID 2% and RAYOS.

Crealta Acquisition

Adds Orphan Medicine KRYSTEXXA to Rheumatology Business

Expect first 12 months sales of $70 – $80mm and $45 – $50mm in adjusted EBITDA

Krystexxa® (pegloticase) Injection, 8mg/mL, for Intravenous Infusion

Indication	Chronic refractory gout in adults(1)
Description	PEGylated uric acid specific enzyme
Route of Administration	IV Infusion every 2 weeks; 12-13 treatments for a complete course of therapy
Regulatory Status (U.S.)	Marketed; Orphan Designation (~50k patients)
Intellectual Property	Patent protection out to 2027
Rights	Worldwide
Status	Marketed in the U.S. Approved, not marketed in EU

Aggressive Clinical Plan to Address Immunogenicity

(1) Please see full prescribing information, available at www.KRYSTEXXA.com.

Strong Track Record of Successful Acquisitions

Success is Defined by Post-Acquisition Volume Growth

January 2016
Acquisition of Crealta

Krystexxa® (pegloticase) Injection, 8mg/mL, for Intravenous Infusion

MIGERGOT® (ergotamine tartrate & caffeine suppositories)

May 2015
Acquisition of Hyperion Therapeutics

RAVICTI® (glycerol phenylbutyrate) Oral Liquid

BUPHENYL® (1) (sodium phenylbutyrate)

October 2014
Acquisition of PENNSAID 2% from Nuvo Research

PENNSAID® (2) (diclofenac sodium topical solution) 2% w/w

September 2014
Acquisition of Vidara Therapeutics

ACTIMMUNE® (Interferon gamma-1b)

November 2013
Acquisition of VIMOVO from AstraZeneca

VIMOVO® (3) (naproxen/esomeprazole magnesium) 375/20 -500/20 mg delayed-release tablets

April 2010
Acquisition of Nitec Pharma

RAYOS® (4) (Prednisone) Delayed-release Tablets

Maximize shareholder value creation by executing aggressive business development via medicine / company acquisitions

(1) BUPHENYL is known as AMMONAPS outside the United States.
(2) PENNSAID 2% was re-launched by Horizon sales force in January 2015.
(3) VIMOVO was re-launched by Horizon sales force in January 2014.
(4) RAYOS is known as LODOTRA outside the United States.

Success Drives Evolving Business Development Strategy

Enables Expansion to Longer Life, Global Expansion and Development Stage Assets



(1) Development-stage opportunities may not be immediately accretive.

2013 – 2015 Net Sales CAGR ~220%

Rapid Diversification with no Medicine >25% in 2015

Strong quarterly net sales growth and diversification over the last 12 quarters



(1) Q4 2015 sales estimate based on midpoint of full-year 2015 guidance provided on Nov. 6, 2015. By this presentation, Horizon is not updating or confirming the prior guidance.

$2B+ in 2020 Net Sales in Long-Range Plan

Net Sales More than Double in Four Yrs with Orphan Medicines Becoming Majority

($ in millions)



Note: Excludes any future business development activities.

(1) Represents financial guidance issued November 6, 2015. By this presentation Horizon is not updating or confirming the prior guidance.

(2) Represents financial guidance issued January 12, 2016.

(3) Horizon internal goals based on long-range plan presented November 9, 2015. Does not include ACTIMMUNE in certain cancers or the acquisition of Crealta.

Orphan Business Long-Range Plan

~$1.3 - $2bn+ Annual U.S. Net Sales Opportunity in 2020(1)



(1) Horizon estimate. Midpoint of ranges are represented on chart for FA and cancer (kidney and bladder).
(2) ACTIMMUNE, RAVICTI and BUPHENYL.

Strong Financial Position

September 30, 2015

Strong capital structure with net debt of $590M at September 30, 2015

($ in millions)	September 30, 2015
Cash and cash equivalents	**$684**
Senior secured term loans - Due 2021	399
2.5% exchangeable senior notes - Due 2022	400
Senior notes - Due 2023	475
Total Debt (Face Amount)	**$1,274**
Less debt discount	(133)
Total Debt (Book Value)	**$1,141**
Shares outstanding	**159,267,370**

Horizon Pharma: When Patients Benefit, Everyone Benefits

Patients, Providers, Our Company, Our Shareholders & Healthcare System

- **Helping people live better lives by building a biopharmaceutical company of tomorrow.**
- **Putting patients first by redefining how they access their medicines.**
- **Investing in differentiated medicines that address the challenges faced by patients living with rare diseases.**
- **Fast-growing, profitable company driven by a highly successful commercial model diversified across three business units.**
- **Strong cash flows enabling a disciplined and proven business development strategy.**

LAILA – Age 10 – California RAVICTI Patient; suffers from a Urea Cycle Disorder (UCD)

Horizon Pharma plc

BIO CEO & Investor Conference

February 8, 2016

HORIZON PHARMA

GAAP to Non-GAAP Reconciliation

EBITDA

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2014	2013	2014	2013
	(Unaudited)		(Unaudited)	
EBITDA and Adjusted EBITDA:				
GAAP Net Loss	$ (31,647)	$ (102,901)	$ (263,603)	$ (149,005)
Depreciation	509	313	1,702	1,174
Amortization and accretion:				
Intangible amortization expense	15,836	3,158	32,306	8,136
Accretion of royalty liabilities	3,403	-	9,020	-
Amortization of deferred revenue	(166)	(160)	(644)	(930)
Amortization of inventory step-up adjustment	9,525	-	11,065	-
Interest expense, net (including amortization of debt discount and deferred financing costs)	10,218	2,128	23,826	12,774
Benefit for income taxes	(2,817)	(154)	(6,084)	(1,121)
EBITDA	$ 4,861	$ (97,616)	$ (192,412)	$ (128,972)
Non-GAAP adjustments:				
Remeasurement of VIMOVO and ACCTIMMUNE royalty liabilities	(2,373)	-	10,660	-
Bargain purchase gain	-	-	(22,171)	-
Loss on derivative revaluation	-	69,300	214,995	69,300
Vidara acquisition costs	2,776	-	48,427	-
PENNSAID acquisition costs	408	-	408	-
Loss on induced debt conversion / debt extinguishment	29,390	26,404	29,390	26,404
Secondary offering costs	2,857	-	2,857	-
Share-based compensation	3,087	1,808	13,198	5,014
Total of Non-GAAP adjustments	$ 36,145	$ 97,512	$ 297,764	$ 100,718
Adjusted EBITDA	$ 41,006	$ (104)	$ 105,352	$ (28,254)
VIMOVO and ACTIMMUNE royalties for period	$ (6,202)	$ -	$ (18,264)	$ -
Adjusted EBITDA (Net of Royalties)	$ 34,804	$ (104)	$ 87,088	$ (28,254)
Non-GAAP Gross Profit:				
GAAP net sales	$ 103,841	$ 30,080	$ 296,955	$ 74,016
GAAP cost of goods sold	32,680	5,255	78,753	14,625
GAAP gross profit	$ 71,161	$ 24,825	$ 218,202	$ 59,391
GAAP gross profit %	69%	83%	73%	80%
Non-GAAP Gross Profit:				
GAAP gross profit	$ 71,161	$ 24,825	$ 218,202	$ 59,391
Non-GAAP gross profit adjustments:				
Remeasurement of VIMOVO and ACCTIMMUNE royalty liabilities	(2,373)	-	10,660	-
Intangible amortization expense	15,836	3,158	32,306	8,136
Accretion of royalty liabilities	3,403	-	9,020	-
Amortization of inventory step-up adjustment	9,525	-	11,065	-
Depreciation	109	91	369	350
Total of Non-GAAP adjustments	$ 26,500	$ 3,249	$ 63,420	$ 8,486
Non-GAAP gross profit	$ 97,661	$ 28,074	$ 281,622	$ 67,877
Non-GAAP gross profit %	94%	93%	95%	92%
Non-GAAP Cash Provided By (Used) in Operating Activities:				
GAAP cash provided by (used in) operating activities	$ 10,079	$ (11,178)	$ 27,549	$ (54,287)
Cash payments related to Vidara acquisition costs	5,796	-	34,830	-
Cash payments post closing of certain transaction costs of Vidara	-	-	14,116	-
Cash payments associated with induced debt conversion	16,690	-	16,690	-
Non-GAAP cash provided by (used in) operating activities	$ 32,565	$ (11,178)	$ 93,185	$ (54,287)

Horizon Pharma plc

BIO CEO & Investor Conference

February 8, 2016

HORIZON PHARMA